iLite® ADCC Bioassays
A biologically relevant and powerful way to assess CD32/FcyRlla induced effects.
Receive your quote directly from the manufacturer.
The iLite ADCC product portfolio is based on a reporter gene system and offers a convenient and powerful way of measuring the efficacy antibodies have to elicit ADCC through the CD16/ FcyRIIIa receptor in vitro.
This is achieved by combining a cleverly engineered effector cell, that closely resembles the natural FcγRIIIA signal transduction pathway, with homologous target cells with a controlled antigen expression (+) or depletion (-).
Taken together, Svar Life Science's unique iLite ADCC portfolio offers unparalleled sensitivity for each target and a system that is truly greater than the sum of its parts.
The iLite ADCC product portfolio consists of cell lines provided in an “assay-ready” format for a rapid and convenient workflow and a further reduction in assay variability, enabling their use in antibody screening, characterization, stability, and potency studies.
